干细胞治疗坏死性小肠结肠炎的研究进展

Advances in stem cell therapy for necrotizing enterocolitis

坏死性小肠结肠炎（necrotizing enterocolitis,NEC）是新生儿尤其是早产儿、低出生体重儿的常见肠道疾病.随着现代医疗技术的进步,国内早产儿、极低出生体重儿的救治成功率增加,而NEC发病率有所上升,病死率仍较高.目前临床上对NEC的主要管理措施是保守治疗和手术治疗.干细胞治疗NEC虽仍处于动物实验阶段,其治疗机制尚未完全清楚,但干细胞逐渐成为NEC治疗的研究热点,可能成为新突破.干细胞治疗NEC用于临床实践之前,还需要更多的实验研究支持.

Narcotizing enterocolitis （NEC） is the most common neonatal gastrointestinal emergency,especially in preterm and low-birth-weight infants.Despite a higher survival rate,NEC has remained an important cause of morbidity and mortality.At present,conservative measures and surgical options are available for NEC.Though still limited to animal experiment,stem cell therapy for NEC has promising clinical prospects.Additional animal studies and clinical trials will be required before its widespread clinical application.